Preparation of Adenosine-Containing Artificial Dinucleoside Triphosphates

Article Preview

Abstract:

Two adenosine-containing asymmetrical dinucleoside triphosphates were synthesized via the P(V)–N activation method. The key adenosine 5ʹ-phosphoropiperidate intermediate was obtained by a redox condensation method. The reaction of adenosine phosphoropiperidate with uridine 5ʹ- and cytidine 5ʹ-diphosphates in the presence of 4,5-dicyanoimidazole (DCI) afforded the desired dinucleoside triphosphates in good isolated yields.

You might also be interested in these eBooks

Info:

Periodical:

Pages:

71-74

Citation:

Online since:

October 2014

Export:

Price:

Permissions CCC:

Permissions PLS:

Сopyright:

© 2014 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

* - Corresponding Author

[1] V. Jankowski, M. van der Giet, H. Mischak, M. Morgan, W. Zidek, J. Jankowski. Br. J. Pharmacol., Vol. 157 (2009), p.1142.

DOI: 10.1111/j.1476-5381.2009.00337.x

Google Scholar

[2] B.R. Yerxa, J.R. Sabater, C.W. Davis, M.J. Stutts, M. Lang-Furr, M. Picher, A.C. Jones, M. Cowlen, R. Dougherty, J. Boyer, W.M. Abraham, R.C. Boucher, J. Pharmacol. Exp. Ther. Vol. 302 (2002), p.871.

DOI: 10.1124/jpet.102.035485

Google Scholar

[3] S. Mohamady, S. D. Taylor, J. Org. Chem. Vol. 76 (2011), p.6344.

Google Scholar

[4] N.A. Flores, B.M. Stavrou, D.J. Sheridan, Cardiovasc. Res. Vol. 42 (1999), p.15.

Google Scholar

[5] H. Schlueter, E. Offers, G. Brueggemann, M. van der Giet, M. Tepel, E. Nordhoff, M. Karas, C. Spieker, H. Witzel, W. Zidek, Nature Vol. 367 (1994), p.186.

DOI: 10.1038/367186a0

Google Scholar

[6] K. Nichols, R. Yerxa, J. Kellerman, Expert Opin. Investig. Drugs Vol. 13 (2004), p.47.

Google Scholar

[7] Q. Sun, S. Gong, S. Liu, J. Sun, G. Liu, C. Ma, Tetrahedron Vol. 70 (2014) p.4500.

Google Scholar

[8] S. Yelovitch, J. Camden, G. A. Weisman, B. Fischer, J. Med. Chem. Vol. 55 (2012 ), p.437.

Google Scholar

[9] K. Huang, P.A. Frey, J. Am. Chem. Soc. Vol. 126 (2004), p.9548.

Google Scholar

[10] C.H.V. Hoyle, R.H. Hilderman, J.J. Pintor, H. Schluter, B.F. King, Drug Dev. Res. Vol. 52 (2001), p.260.

Google Scholar

[11] R. Shaver, L. Rideout, W. Pendergast, G. Douglass, G. Brown, L. Boyer, I. Patel, C. Redick, C. Jones, M. Picher, R. Yerxa, Purinergic Signalling Vol. 1 (2005), p.183.

DOI: 10.1007/s11302-005-0648-2

Google Scholar

[12] N. Stern, T. Major, E. Gottlieb, D. Weizman, B. Fischer, Org. Biomol. Chem. Vol. 8 (2010), p.4637.

Google Scholar

[13] J.G. Douglass, R.I. Patel, B.R. Yerxa, S.R. Shaver, P.S. Watson, K. Bednarski, R. Plourde, C.C. Redick, K. Brubaker, A.C. Jones, J.L. Boyer, J. Med. Chem. Vol. 51 (2008), p.1007.

DOI: 10.1021/jm701348d

Google Scholar

[14] H. Maruoka, M.P. Jayasekara, M.O. Barrett, D.A. Franklin, S. Castro, N. Kim, S. Costanzi, T.K. Harden, K.A. Jacobson, J. Med. Chem. Vol. 54 (2011), p.4018.

Google Scholar

[15] H. Ko, R.L. Carter, L. Cosyn, R. Petrelli, S. de Castro, P. Besada, Y. Zhou, L. Cappellacci, P. Franchetti, M. Grifantini, S.V. Calenbergh, T.K. Harden, K.A. Jacobson, Bioorg. Med. Chem. Vol. 16 (2008), p.6319.

DOI: 10.1016/j.bmc.2008.05.013

Google Scholar